D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Immunopathogenesis and Diagnosis of Tuberculosis and Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome during Early Antiretroviral Therapy
Julian Elliott,Julian Elliott,Julian Elliott,Khol Vohith,Sarun Saramony,Chin Savuth,Chan Dara,Chel Sarim,Sarah Huffam,Robert Oelrichs,Pouv Sophea,Vonthanak Saphonn,John M. Kaldor,David A. Cooper,Mean Chhi Vun,Martyn A. French +15 more
TL;DR: Type 1 effector T cell responses are prominent in ART-associated tuberculosis, but additional immune defects may be more important in paradoxical TB-IRIS.
Journal ArticleDOI
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
Edson D. Moreira,Nicholas Kitchin,Xia Xu,Samuel S. Dychter,Stephen Lockhart,Alejandra Gurtman,John L. Perez,Cristiano A. F. Zerbini,Michael E Dever,Timothy W Jennings,Donald Brandon,Kevin D Cannon,Michael J. Koren,Douglas S Denham,Mezgebe Berhe,David Fitz-Patrick,Laura L. Hammitt,Nicola P. Klein,Haylene Nell,Georgina Keep,Xingbin Wang,Kenneth Koury,Kena A. Swanson,David A. Cooper,Claire M. Lu,Özlem Türeci,Eleni Lagkadinou,Dina B. Tresnan,Philip R. Dormitzer,Ugur Sahin,William C. Gruber,Kathrin U. Jansen +31 more
TL;DR: A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses of the Pfizer–BioNTech vaccine during a median follow-up of 2.5 months.
Journal ArticleDOI
Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention.
Gustavo H Dayan,Naglaa S. Mohamed,Ingrid L. Scully,David A. Cooper,Elizabeth Begier,Joseph Eiden,Kathrin U. Jansen,Alejandra Gurtman,Annaliesa S. Anderson +8 more
TL;DR: Prevention using a prophylactic vaccine would complement the processes oficrobial resistance and emergence of new S. aureus clonal types with increased expression of virulence factors and the capacity to neutralize the host immune response.
Posted ContentDOI
Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report
Mark J. Mulligan,Kirsten E. Lyke,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Kathleen M. Neuzil,Vanessa Raabe,Ruth Bailey,Kena A. Swanson,Ping Li,Kenneth Koury,Warren Kalina,David A. Cooper,Camila Fonter-Garfias,Pei Yong Shi,Ozlem Tuereci,Tompkins Kristin Rachael,Edward E. Walsh,Robert W. Frenck,Ann R. Falsey,Philip R. Dormitzer,William C. Gruber,Ugur Sahin,Kathrin U. Jansen +24 more
TL;DR: Safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, support further evaluation of this mRNA vaccine candidate.
Journal ArticleDOI
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
John Zaunders,Philip Cunningham,Anthony D. Kelleher,Gilbert R. Kaufmann,Angel B. Jaramillo,Rowanne Wright,Don Smith,Pat Grey,Jeanette Vizzard,Andrew Carr,Andrew Carr,David A. Cooper,David A. Cooper +12 more
TL;DR: Early antiretroviral therapy resulted in clearance of viremia and prevented loss of crucial CD4 subsets, and the persistence of HIV-1 DNA together with increased CD8 T lymphocyte turnover and activation indicate continued expression of viral antigens.